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Abstract: Picotamide is an antiplatelet drug with a dual inhibitory action. Thus, picotamide 
inhibits both thromboxane A2 (TxA2) receptors and TxA2 synthase and, at variance with aspirin, 
does not interfere with endothelial prostacyclin (PGI2) production. Two large randomized 
trials have been performed to assess the clinical efﬁcacy of picotamide in patients at risk 
of atherothrombosis. The ADEP study compared peripheral artery disease (PAD) patients 
randomized to picotamide or placebo. This study did not show a signiﬁcant reduction of 
cardiovascular events by picotamide but a subgroup analysis showed its potential usefulness 
in patients with diabetes. To investigate this issue further, the DAVID study recently enrolled 
diabetic patients with PAD randomized to picotamide versus aspirin; the results showed 
a signiﬁcant reduction of overall mortality in the picotamide group. Moreover long-term 
picotamide treatment in diabetes promotes the reduction of microalbuminuria and the inhibition 
of growth of carotid plaques. These data suggest that picotamide may represent an interesting 
drug to be further investigated in future trials in the atherothrombotic setting.
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Introduction
Picotamide, a derivative of methoxy-isophtalic acid, is an antiplatelet drug that inhibits 
both thromboxane A2 (TxA2) receptors and TxA2 synthase. As concentrations of the 
molecule needed to inhibit both pathways are almost equivalent (Modesti et al 1994), 
picotamide may exert a dual pharmacological action in vivo and be potentially useful 
in various clinical settings characterized by atherosclerotic disease. Picotamide has 
been investigated in two large clinical trials in patients suffering from cardiovascular 
events, ie, in patients with peripheral artery disease (PAD) (Balsano and Violi 1993) 
and in patients with diabetes (Neri Serneri et al 2004). This review will focus on the 
results of these two trials and on the future perspective of picotamide in the setting 
of cardiovascular disease.
Pharmacology
Upon platelet activation, arachidonic acid is released from platelet membrane by 
phospholipase A2 (PLA2)-mediated degradation of membrane phospholipids and is 
converted to prostaglandin endoperoxides, as prostaglandin G2 (PGG2) and prostaglan-
din H2 (PGH2), via cyclooxygenase-1 (COX-1) activation. PGH2 is then converted 
by TxA2 synthase to TxA2. Furthermore, PGH2 participates in cycles of ampliﬁcation 
signals for platelet activation by recruitment of other platelets through interaction with 
the same receptors of TxA2 (Parise et al 1984; FitzGerald 1991).
TxA2 has detrimental effects on the arterial tone by virtue of its vasoconstrictor 
property, an effect that is counteracted by endothelial molecules, such as nitric oxide 
and prostacyclin (PGI2), a cyclo-oxygenase-derived substance.Vascular Health and Risk Management 2007:3(1) 94
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Aspirin is the most widely used antiplatelet drug to 
prevent cardiovascular events in patients with acute or 
chronic cardiovascular diseases (Antithrombotic Trialists’ 
Collaboration 2002). Aspirin irreversibly acetylates 
COX-1, thereby preventing TxA2 in platelets and PGI2 in the 
endothelium. Although endothelial production of PGI2 
is inhibited only in part by aspirin (Caughey et al 2001), 
since the 1980s a number of drugs has been developed to 
interfere selectively with TxA2 activity, without inhibiting 
endothelial PGI2 production (Landolﬁ et al 1988). Among 
these drugs picotamide attracted the attention of researchers 
for its ability to inhibit both TxA2 platelet synthase and 
platelet TxA2 receptors and, in turn, platelet aggregation. 
In particular, Violi et al (1988) showed that picotamide at 
micromolar concentrations inhibited platelet aggregation 
induced by various agonists, such as ADP, arachidonic 
acid, and collagen. Furthermore the reduction of platelet 
aggregation was directly related to the inhibition of TxA2 
production. Unlike aspirin, picotamide was not able to 
reduce the release of PGI2 by endothelium. Taken together 
these results demonstrated that picotamide reduced platelet 
function by inhibiting TxA2 production without affecting 
cyclo-oxygenase activity. These data were conﬁrmed by 
the in vivo study, which showed a consistent reduction of 
platelet aggregation and TxA2 production in platelets from 
eight healthy volunteers taking picotamide 1200 mg/die 
(Violi et al 1988). Moreover Gresele et al (1989) showed 
that picotamide, apart from reducing the synthesis of TxA2, 
enhanced the formation of PGE2 in platelets and favored the 
formation of PGI2 by aspirinated endothelial cells.
The evidence that picotamide almost completely inhibits 
platelet aggregation induced by the TxA2 analogous U46619 
suggested that this drug also has an inhibitory effect on 
TxA2 receptors (Berrettini et al 1990). In this regard, an 
in vitro study showed that picotamide displaced a selective 
radioligand of TxA2 receptor from platelets, so indicating 
that it directly inhibits this receptor (Modesti et al 1989). 
Other pharmacological studies demonstrated that picotamide 
binding to thromboxane A2 receptors is initially reversible 
and becomes progressively non-displaceable (Modesti et al 
1991, 1994).
The reduction of circulating platelet-derived TxA2 levels 
induced by picotamide not only inhibits platelet aggregation, 
but also has important consequences for the inﬂammatory 
processes of atherosclerotic plaque. TxA2 has an important 
role in regulating vascular tone, as it induced endothelin-1 
(ET-1) in both endothelium and smooth muscle cells (Chua 
et al 1996). As a consequence, the reduction of TxA2 
platelet formation induced by picotamide administration 
decreases vessel tone by reducing the circulating levels of 
endotelin-1 (Saitta et al 1998). Moreover picotamide reduces 
smooth muscle cell proliferation as TxA2 is a mythogenic 
stimulus: in vitro studies with picotamide demonstrated that 
it inhibits DNA synthesis of smooth muscle cells incubated 
with U46619 (a TxA2 analog) alone and also with other 
mythogenic molecules such as EGF or PDGF (Ratti 
et al 1998). Finally, it should be mentioned that in vitro 
as well as in vivo studies documented an antiplatelet and 
antivasoconstrictor property of picotamide that is unrelated to 
inhibition of TxA2 formation, such as inhibition of serotonin-
induced platelet aggregation (Vezza et al 1997).
Platelet activation and aspirin in diabetes
Diabetes is a clinical setting characterized by enhanced platelet 
activation that depends in part on increased platelet production 
of thromboxane A2. In fact, Davì et al (1990) showed that 
urinary thromboxane B2 (TxB2), a stable metabolite of 
TxA2, was significantly higher in patients with type 2 
diabetes than in controls. Moreover, tight diabetic control 
with insulin therapy reduced urinary 11-deydrothromboxane 
B2 by almost 50%, while aspirin therapy reduced this urinary 
metabolite by 80%. Recovery of impaired excretion of such 
molecules occurred after an aspirin wash-out of 10 days, 
suggesting the platelet origin of thromboxane A2.
Aspirin has been used in patients with diabetes to 
prevent cardiovascular complications, but the results are 
disappointing because only a slightly reduction in clinical 
outcomes has been observed compared with patients affected 
by other cardiovascular risk factors (Antithrombotic Trialists’ 
Collaboration 2002). The reason why diabetic patients are 
less sensitive to aspirin than non-diabetic ones is unclear. An 
enhanced turnover of platelets has been observed in diabetic 
patients, a phenomenon that could limit the antiplatelet effect 
of aspirin. However, more data are necessary to support such 
a hypothesis (Csiszar et al 2002; Di Minno and Violi 2004; 
Gresele and Migliacci 2004). 
A chronic inﬂammatory state is often associated with 
diabetes and may be responsible for platelet activation via 
oxidative stress-mediated formation of isoprostanes (Patrono 
and FitzGerald 1997). Thus, these molecules are products of 
non-cyclooxygenase oxidative modiﬁcations of arachidonic 
acid due to oxidative stress-mediated modification of 
membrane phospholipids or circulating LDLs, and are 
characterized by potent vasoconstrictor and pro-aggregatory Vascular Health and Risk Management 2007:3(1) 95
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effects. Their effects in activating platelets are mediated 
by receptors closely related to TxA2 receptors and may be 
potentially counteracted by TxA2 receptor antagonists such 
as picotamide. So far, however, no data are available on 
the effect of picotamide on isoprostanes-induced platelet 
activation.
Platelet activation and aspirin 
in peripheral arterial disease
Platelet activation as assessed by urinary excretion of TxB2 
has been studied in patients with PAD and matched controls 
(Davì et al 1997). This study demonstrated enhanced values 
of urinary TxB2 in PAD patients compared with control. Such 
differences, however, seemed to be attributable essentially to 
the coexistence of risk factors for atherosclerotic disease such 
as hypercholesterolemia, diabetes, or smoking habit. Thus, 
in PAD patients without such risk factors, urinary excretion 
of TxB2 was similar to that in controls, suggesting that the 
risk factors rather than atherosclerotic disease per se are 
responsible for enhanced production of TxB2.
Despite these data suggesting a role for COX-1 in the 
pathophysiology of PAD, the clinical efﬁcacy of aspirin 
in this clinical setting is uncertain. Prospective studies 
with adequate sample size have never been performed. 
Data on the effects of aspirin in preventing cardiovascular 
disease stem essentially from meta-analysis, which have not 
provided deﬁnite ﬁndings on its potential efﬁcacy (WAVE 
Investigators 2006). Therefore further studies with adequate 
sample size should be performed to investigate the clinical 
efﬁcacy of aspirin in preventing cardiovascular disease in 
this clinical setting.
Clinical studies
Since the 1970s, prospective studies have shown a strong 
association between cardiovascular events and type 1 or 
type 2 diabetes mellitus (Garcia et al 1974; Panzram 1987). 
Moreover in recent decades the beneﬁcial effects of aspirin 
and other antiplatelet drugs against myocardial infarction, 
stroke, and other vascular events have been well documented 
(Antithrombotic Trialist’s Collaboration 2002). However, 
aspirin treatment seems to be less useful in diabetic patients 
compared with patients with other risk factors in primary or 
secondary prevention of cardiovascular complications. In this 
regard a recent meta-analysis analysed 4961 subjects among 
9 trials and showed only a 7% odds reduction of vascular 
complications in diabetic patients treated with aspirin versus 
placebo. Although this reduction hardly reached statistical 
signiﬁcance, it is consistently less when compared with the 
proportional reduction over 195 studies analyzed by the 
meta-analysis (22% versus 7%) (Antithrombotic Trialist’s 
Collaboration 2002).
As reported above, evidence for any beneﬁts of aspirin 
treatment in patients with PAD is insufficient (WAVE 
Investigators 2006). Thus, in contrast to other authorities 
(Clagett et al 2004), the Food and Drug Administration expert 
panel did not provide any indication of aspirin treatment 
for patients with PAD (Food and Drug Administration 
1998). This strongly suggests the need for developing new 
antiplatelet drugs potentially useful in diabetes and PAD.
The first large randomized trial (ADEP trial) on 
picotamide investigated its clinical usefulness in patients with 
PAD (Balsano and Violi 1993). For this study 2304 patients 
were consecutively enrolled, allocated to either placebo 
or picotamide (300 mg bid), and followed for 18 months. 
Endpoints of the study were major events (ie, cardiovascular 
death, myocardial infarction, stroke, or amputation) and 
minor events (unstable angina, transient ischemic attack, 
hypertension, renal failure, deterioration of PAD). The 
“intention to treat analysis” showed a risk reduction (18.9%) 
in the combined endpoints, major plus minor events, in 
the picotamide group compared with the controls, which, 
however, did not reach statistical signiﬁcance; conversely, 
“on treatment analysis” showed a higher and statistically 
signiﬁcant reduction (22.8%) in the same endpoints. Side-
effects such as bleeding were almost identical in the two 
groups. As the authors suggested, the lack of any beneﬁcial 
effects of picotamide against major events could have been 
related to the low occurrence of these events during the 
follow-up; this phenomenon may be related to a bias in 
patient selection, which excluded high-risk patients.
The capacity of picotamide to prevent vascular 
complications was, however, magniﬁed when claudicant 
patients affected by diabetes were taken into account. Thus, 
a sub-study of the ADEP trial retrospectively analyzed 438 
diabetic patients and observed a risk reduction of 45.2% 
of combined major and minor events in those treated with 
picotamide compared with those treated with placebo (Milani 
et al 1996). On the basis of this post-hoc analysis a new 
randomized trial (the DAVID trial) was speciﬁcally designed 
for diabetic patients with PAD (Neri Serneri et al 2004). 
Thus, 1209 patients were enrolled and randomly assigned 
to picotamide (600 mg bid) or aspirin (320 mg/day) and 
followed for 2 years. The primary endpoint was the overall 
mortality and the secondary one was the combined incidence Vascular Health and Risk Management 2007:3(1) 96
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of death and major cardiovascular events. Mortality was 
signiﬁcantly lower in picotamide-treated patients than in 
those treated with aspirin, showing a relative risk of reduction 
of 45%; furthermore the incidence of gastrointestinal 
bleeding was much lower in the picotamide group than in 
the aspirin group. The secondary endpoint did not show any 
signiﬁcant difference between two populations, showing only 
a non-signiﬁcant trend in favor of patients taking picotamide 
(Tables 1 and 2). As pointed out by the authors, a possible 
bias relative to the high proportion of patients (about 20% in 
each group) who discontinued the trial because of a non-fatal 
events may have underestimated the real incidence of the 
secondary endpoints; moreover it is possible that the sample 
size of the study was insufﬁcient to detect any difference in 
these end-points between the two groups (Tables 1 and 2). 
Comparison of the results achieved by the ADEP and DAVID 
trials also raises the question as to whether the differences 
seen are dependent on the fact that TxA2 production is more 
relevant for atherosclerotic progression in PAD patients with 
diabetes compared with PAD without diabetes, or whether 
the different dosage of picotamide (600 mg vs 1200 mg in 
the ADEP and DAVID respectively) has a different impact 
on clinical outcome. Further studies are therefore necessary 
to explore the relationship between picotamide dosage and 
TxA2 inhibition in vivo.
In conclusion, despite the interesting ﬁndings relative 
to the reduction of overall mortality and the better safety 
of picotamide compared with aspirin, other clinical trials 
are necessary in order to clarify the real clinical beneﬁt of 
picotamide for ischemic non-fatal events in PAD patients 
with diabetes. 
The beneﬁcial effects of long-term picotamide in diabetic 
patients are also corroborated by its capacity in reducing 
microalbuminuria and in inhibiting growth of carotid 
plaques.
Thirty type 2 diabetic, normotensive patients, all 
characterized by microalbuminuria at rest, were randomized 
to picotamide 300 mg/day or placebo for 1 year. Results 
showed a reduction of microalbuminuria at rest and after 
exercise without signiﬁcant changes in metabolic control 
in the picotamide-treated patients compared with control 
subjects. Moreover, a linear correlation was found between 
urinary thromboxane excretion and microalbuminuria after 
stress-test (Giustina et al 1998). These ﬁndings suggest an 
interesting relationship between thromboxane formation and 
vascular complication of type 2 diabetes. Thus, the fact that 
picotamide is more effective in reducing microalbuminuria 
induced by stress-test than at rest suggests that the 
vasoconstrictor properties of TxA2 may be responsible for 
its physiopathological action on glomerular activity.
The effects on plaque progression are also supported by 
a 2-year prospective study that demonstrated a reduction 
of carotid plaque evolution in diabetic patients, affected by 
non-stenotic and asymptomatic carotid atherosclerosis. In 
Table 1 Baseline characteristics and side-effects of both ADEP and DAVID trials
  ADEP study  DAVID study
  Picotamide  Placebo  Picotamide  Aspirin
Dosage  300 mg bid    600 mg bid  320 mg od
Clinical characteristics
  n = 1150  n = 1154  n = 603  n = 606
Age  63.4 + 7.3   62.9 + 7.4  63.8 + 7.2  64.6 + 7.3
Diabetes  20%  18%  100%  100%
PAD  100%  100%  100%  100%
Smoke   39.6%  37.1%  30.5%  28.4%
Hypertension  34.5%  37.5%  58.2%  55.6%
Dyslipidemia  36.5%  35.8%  38%  38.4%
Previous stroke  1.4%  1.7%  10.4%  10.2%
Coronary heart disease  15%  12.7%  19.4%  19%
Side-effects
Gastro-intestinal  11.1%  12%  10.9%  18.3%
Total  14.3%  13.5%  25.6%  33.9%
Abbreviations: bid, twice a day; od, once a day; PAD, peripheral artery disease.Vascular Health and Risk Management 2007:3(1) 97
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extension, 50 type II normotensive diabetic patients with 
asymptomatic mild or moderate non-stenotic (<50%) carotid 
atherosclerotic plaque were randomly given picotamide 300 
mg/day or placebo; after 2 years, lesion numbers and percent-
age stenosis in the picotamide group were signiﬁcantly lower 
than in the placebo group (Cocozza et al 1995).
Conclusion
The data so far reported on the effect of picotamide in patients 
at risk of atherothrombosis are of particular interest overall 
because the clinical efﬁcacy of picotamide has emerged in 
patients with diabetes, who seem to be less sensitive to the 
effect of other antiplatelet drugs such as aspirin. Although 
the number of patients included in trials with picotamide 
was not limited, trial results are still insufﬁcient to provide 
deﬁnite conclusions on its clinical efﬁcacy. Therefore the 
results of the above-reported trials should represent a useful 
background to further test the hypothesis that an antiplatelet 
drug with a dual mechanism of action such as picotamide 
may be beneﬁcial in preventing the cardiovascular events 
in patients with atherothrombosis. In this context it is 
interesting to mention a recent experimental study in which 
a combination of drugs inhibiting COX-1 and TxA2 receptor 
antagonist has been investigated in an animal model of 
atherosclerosis (Cyrus et al 2006). The study showed that 
such a combination possesses a greater anti-atherosclerotic 
property than the single drug, so providing further support 
for the potentially clinical usefulness of drugs with dual 
COX-1 and TxA2 receptor inhibition. The DAVID study 
suggests that in patients with PAD and diabetes, antiplatelet 
drugs with similar pharmacological characteristics should 
be investigated. The study should be prospective and include 
more than 1500 patients (the sample size primarily considered 
by the DAVID committee as number of patients necessary to 
detect a signiﬁcant difference between picotamide and aspirin), 
and should obviously compare picotamide versus aspirin in a 
follow-up of 2 years. Such a study could provide more deﬁnite 
data on the clinical efﬁcacy of picotamide in this clinical setting 
and potentially open new avenues in an atherosclerotic sub-
setting where the clinical efﬁcacy of aspirin is still debated.
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